List of medicines under additional monitoring
https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring
Clinical Trials Information System Webinar: Last Year of Transition
https://www.ema.europa.eu/en/events/clinical-trials-information-system-webinar-last-year-transition
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024
Clinical trial’s transition to new EU system – one year left
https://www.ema.europa.eu/en/news/clinical-trials-transition-new-eu-system-one-year-left
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024
Major update of the SME user guide
https://www.ema.europa.eu/en/news/major-update-sme-user-guide
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 January 2024
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-january-2024
Midterm report on 2025 network strategy highlights good progress during critical period of the pandemic
https://www.ema.europa.eu/en/news/midterm-report-2025-network-strategy-highlights-good-progress-during-critical-period-pandemic
Hemovigilance: ANSM changes the way blood donors report adverse events
https://ansm.sante.fr/actualites/hemovigilance-lansm-fait-evoluer-la-declaration-des-effets-indesirables-donneurs-de-sang
Artificial intelligence workplan to guide use of AI in medicines regulation
https://www.ema.europa.eu/en/news/artificial-intelligence-workplan-guide-use-ai-medicines-regulation